← Back to Search

Palliative Care for Blood Cancers (PEACE Trial)

N/A

Recruiting

Led By Patrick C Johnson, MD

Research Sponsored by Massachusetts General Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosis of a hematologic malignancy

Receiving autologous adoptive cellular therapy (ACT) at MGH with an FDA approved cellular therapy product

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to day 90

Awards & highlights

PEACE Trial Summary

This trial seeks to learn if a palliative care intervention, PEACE, can improve quality of life and experience of those with lymphoma, leukemia, or multiple myeloma who receive adoptive cellular therapy. 90 people will be randomly assigned to receive either PEACE+usual oncology care or only usual oncology care. Trial duration: up to 2 years.

Who is the study for?

This trial is for adults over 18 with blood cancers like Lymphoma, Leukemia, or Multiple Myeloma who are getting a special treatment called ACT at MGH and can complete surveys in English. It's not for those with cognitive issues or uncontrolled mental illness that makes it hard to follow the study rules, or those already in palliative care.Check my eligibility

What is being tested?

The study tests if adding a specific type of supportive care (PEACE) to regular cancer treatment helps improve life quality for patients undergoing ACT. Participants will be randomly placed into two groups: one receiving PEACE plus usual care, and the other just usual care.See study design

What are the potential side effects?

Since this trial focuses on palliative care rather than direct medical treatments, side effects aren't the main concern. However, participants may experience various emotional responses to discussions about their illness and future during palliative sessions.

PEACE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with a blood cancer.

Select...

I am getting a cell therapy treatment at MGH that is approved by the FDA.

Select...

I am 18 years old or older.

PEACE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to day 90

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to day 90

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to day 90 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percentage of Eligible Participants Enrolled to Palliative Care Intervention (PEACE) (Feasibility)

Secondary outcome measures

Acceptability

Anxiety Symptoms

Coping

+6 more

PEACE Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Palliative Care Intervention (PEACE) GroupExperimental Treatment1 Intervention

Participants will be randomly assigned, and stratified by disease, to the PEACE Group. Participants will meet with palliative care (PC) clinician within 1 week of T-cell collection and within 72 hours of hospital admission for ACT. Participants will meet with PC clinician at least 2 x weekly during hospitalization. PC clinician will follow participants up to one year after randomization (or enrollment for the open pilot) and will meet participant at least 2 x weekly during inpatient hospitalizations. Participants will complete follow-up study assessments on pre-determined days per protocol. The assessments will be filled out remotely or via paper. Participants will complete exit interviews in the open pilot only.

Group II: Usual Care GroupActive Control1 Intervention

Participants will be randomly assigned, and stratified by disease, to the Usual Care Group and will receive standard care for ACT.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Palliative Care

2011

N/A

~1270

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor

2,933 Previous Clinical Trials

13,198,391 Total Patients Enrolled

45 Trials studying Leukemia

4,545 Patients Enrolled for Leukemia

Conquer Cancer FoundationOTHER

19 Previous Clinical Trials

3,885 Total Patients Enrolled

Patrick C Johnson, MDPrincipal InvestigatorMassachusetts General Hospital

1 Previous Clinical Trials

80 Total Patients Enrolled

Media Library

Palliative Care Clinical Trial Eligibility Overview. Trial Name: NCT05646576 — N/A

Leukemia Research Study Groups: Palliative Care Intervention (PEACE) Group, Usual Care Group

Leukemia Clinical Trial 2023: Palliative Care Highlights & Side Effects. Trial Name: NCT05646576 — N/A

Palliative Care 2023 Treatment Timeline for Medical Study. Trial Name: NCT05646576 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research in need of more participants?

"Clinical trials.gov indicates that this medical study, initially posted on December 8th 2022, is no longer recruiting patients. Nevertheless, there are 5862 other clinical studies actively seeking participants at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

Patrick C. Johnson, MD 2022. "Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05646576.

All > Leukemia